Given that PAK1 regulates the cytoskeleton and microtubule inhibitors are used as standard-of-care chemotherapy in advanced breast cancer, we explored the molecular and cellular mechanisms for this therapeutic combination and showed increased anti-tumor efficacy in breast cancer cells. Here, PAK1 is linked to neoplasm.